Pipeline

Candidate
PreclinicalPre
Phase 1Ph1
Phase 2Ph2
Phase 3Ph3
Hematology
Hematology
PreclinicalPre
Phase 1Ph1
Phase 2Ph2
Phase 3Ph3
KER-050* Therapeutic Protein
KER-050* Therapeutic Protein
Myelodysplastic syndromes
Myelodysplastic syndromes
KER-050* Therapeutic Protein
KER-050* Therapeutic Protein
Myelofibrosis
Myelofibrosis
Pulmonary & Cardiovascular
Pulmonary & Cardiovascular
PreclinicalPre
Phase 1Ph1
Phase 2Ph2
Phase 3Ph3
KER-012 Therapeutic Protein
KER-012 Therapeutic Protein
Pulmonary arterial hypertension
Pulmonary arterial hypertension
Obesity & Neuromuscular
Obesity & Neuromuscular
PreclinicalPre
Phase 1Ph1
Phase 2Ph2
Phase 3Ph3
KER-065 Therapeutic Protein
KER-065 Therapeutic Protein
Preclinical
Preclinical
PreclinicalPre
Phase 1Ph1
Phase 2Ph2
Phase 3Ph3
Musculoskeletal
Musculoskeletal
Obesity
Obesity
Undisclosed Assets
Undisclosed Assets

* Keros Therapeutics has granted an exclusive license to Hansoh (Shanghai) Healthtech Company Limited to develop, manufacture and commercialize KER-050 within the territories of mainland China, Hong Kong, and Macau. Keros Therapeutics exclusively owns rights to all other territories.

Product Candidates

KER-050 is an investigational activin receptor type IIA (ActRIIA) fusion protein designed to inhibit select TGF-β ligands, including activin A. Based on data from our completed Phase 1 clinical trial and multiple preclinical studies, we believe KER-050 has the potential to increase red blood cell and platelet production by acting across the spectrum of cellular differentiation and maturation in hematopoiesis while also improving bone health.

We are developing KER-050 for the treatment of ineffective hematopoiesis in myelodysplastic syndromes (MDS) and myelofibrosis (MF), where the impact of the disease in the bone marrow microenvironment can contribute to anemia, thrombocytopenia, neutropenia and an increased risk of acute myeloid leukemia. For more information about our ongoing Phase 2 clinical trials in MDS and MF, click here.

KER-012 is an investigational modified activin receptor type IIB (ActRIIB) fusion protein being developed for the treatment of pulmonary arterial hypertension (PAH) and cardiovascular disorders. KER-012 is designed to normalize blood vessel thickness and heart function by inhibiting select TGF-β ligands, including activin A, activin B and myostatin (GDF8)—which stimulate smooth muscle hypertrophy and fibrosis—while sparing the bone morphogenic protein (BMP) ligands. For more information about our ongoing Phase 2 clinical trial in PAH, click here.

KER-065 is an investigational selective activin receptor ligand trap being developed for the treatment of obesity and neuromuscular disorders. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A to increase skeletal muscle and bone mass, increase fat metabolism and reduce fibrosis. We have initiated a Phase 1 clinical trial of KER-065 in a healthy volunteer adult population, and following the completion of this trial, we plan to initiate a proof-of-concept trial of KER-065 in obese patients.

Two male Keros Therapeutics scientists reviewing data on a computer monitor